Prelude Therapeutics regains Nasdaq minimum bid price compliance as of Sept 18, 2025

Prelude Therapeutics Inc

Received Nasdaq non-compliance notice on March 27, 2025 for failing $1.00 bid price requirement.
On September 18, 2025, Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.
Common stock (PRLD) remains listed on Nasdaq Global Select Market with bid price issue resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.